RIVERVEST
RiverVest is a venture capital firm which focuses on identifying and shaping early stage life science companies that creates shareholder values. Their team’s domain experience allows them to identify, find, and actively incubate promising life science companies in the medical device and biopharmaceutical industries. It provides practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward. It also invests in selected later-stage life science companies to diversify risk and maximize portfolio returns. RiverVest is a U.S.-based company that was founded in 2000 by Jay W. Schmelter.
RIVERVEST
Industry:
Finance Financial Services Venture Capital
Founded:
2000-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-16 | Bluejay Therapeutics | RiverVest investment in Series B - Bluejay Therapeutics | 41 M USD |
| 2021-12-30 | Good Therapeutics | RiverVest investment in Series B - Good Therapeutics | 8 M USD |
| 2021-11-23 | Venture Med Group | RiverVest investment in Convertible Note - Venture Med Group | N/A |
| 2021-11-02 | Biolinq | RiverVest investment in Series B - Biolinq | 100 M USD |
| 2021-10-19 | Scout Bio | RiverVest investment in Series B - Scout Bio | 33 M USD |
| 2021-07-15 | Wugen | RiverVest investment in Series B - Wugen | 172 M USD |
| 2021-06-23 | Glycomine | RiverVest investment in Series B - Glycomine | 35 M USD |
| 2021-06-01 | Standard Bariatrics | RiverVest investment in Series B - Standard Bariatrics | 35 M USD |
| 2021-05-18 | Sparrow Pharmaceuticals | RiverVest investment in Series A - Sparrow Pharmaceuticals | 50 M USD |
| 2021-04-27 | Arch Oncology | RiverVest investment in Series C - Arch Oncology | 105 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-23 | COVID-19 losses force Wichita Riverfest to cut a third of its staff, including new CEO |